NewAmsterdam Pharma Company N.V. (NAMS)

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 45,481 shares of the business's stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $35.31, for a total value of $1,605,934.11. Following the transaction, the insider directly owned 53,500 shares of the

NAARDEN, the Netherlands and MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:

-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL CVOT blinded event rate tracking in line with observed event rate in BROADWAY--         -- Topline data from RUBENS Phase 3 trial in patients with type 2 diabetes and metabolic syndrome expected by year-end 2026 -- -- $728.9 million in cash, cash equivalents and marketable securities at December 31, 2025 -- NAARDEN, the Netherlands and MIAMI, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced financial results for the full year ended December 31, 2025 and provided a corporate update.

NewAmsterdam Pharma (NASDAQ: NAMS) Chief Financial Officer Ian Somaiya said the company remains encouraged by early observations from its PREVAIL cardiovascular outcomes trial and reiterated plans to provide a mid-year update on study timelines during remarks at Guggenheim's 2026 Emerging Outlook Biotech Summit. PREVAIL timelines and event-rate observations Somaiya pointed back to comments the company made

NAARDEN, The Netherlands and MIAMI, Feb. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 217,000 of NewAmsterdam's ordinary shares to four (4) non-executive new hires. The share options were granted as an inducement material to the employees' acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).

NAARDEN, The Netherlands and MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a virtual fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026 at 8:30 a.m. ET.

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) CAO Louise Frederika Kooij sold 34,400 shares of the stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $32.78, for a total transaction of $1,127,632.00. Following the sale, the chief accounting officer owned 24,353 shares of the company's

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) CAO Louise Frederika Kooij sold 38,172 shares of NewAmsterdam Pharma stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $33.75, for a total transaction of $1,288,305.00. Following the sale, the chief accounting officer directly owned 24,353 shares of

-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 -- -- Phase 3 PREVAIL CVOT overall event rate tracking in line with observed rate in BROADWAY --

NAARDEN, the Netherlands and MIAMI, Jan. 05, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 20,000 of NewAmsterdam's ordinary shares to one non-executive new hire. The share options were granted as an inducement material to the employee's acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) CAO Louise Frederika Kooij sold 43,872 shares of the company's stock in a transaction on Friday, December 26th. The stock was sold at an average price of $35.30, for a total transaction of $1,548,681.60. Following the sale, the chief accounting officer directly owned 15,000 shares of

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) CAO Louise Frederika Kooij sold 26,011 shares of the business's stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $35.68, for a total transaction of $928,072.48. Following the completion of the transaction, the chief accounting officer directly owned

NAARDEN, The Netherlands and MIAMI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 40,000 of NewAmsterdam's ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees' acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).

NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Franklin Resources Inc. raised its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) by 30.6% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 334,212 shares of the company's stock after buying an additional 78,300 shares during the

NAARDEN, The Netherlands and MIAMI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences: